SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-525946"
 

Sökning: id:"swepub:oai:DiVA.org:uu-525946" > Major bleeding in p...

Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone : nationwide cohort study

Fritz Hansson, Astrid (författare)
Uppsala universitet,Kardiologi
Modica, Angelo (författare)
Pfizer AB, Stockholm, Sweden.
Renlund, Henrik, 1979- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
visa fler...
Christersson, Christina (författare)
Uppsala universitet,Kardiologi
Held, Claes, 1956- (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Batra, Gorav (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
visa färre...
 (creator_code:org_t)
BMJ Publishing Group Ltd, 2024
2024
Engelska.
Ingår i: Open heart. - : BMJ Publishing Group Ltd. - 2053-3624. ; 11:1
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Amiodarone is an established treatment for atrial fibrillation (AF) but might interfere with the metabolism of apixaban or warfarin. Therefore, the aim was to investigate the occurrence of major bleeding among patients with AF treated with amiodarone in combination with apixaban or warfarin.Methods Retrospective observational study using Swedish health registers. All patients with AF in the National Patient Register and the National Dispensed Drug Register with concomitant use of amiodarone and warfarin or apixaban between 1 June 2013 and 31 December 2018 were included. Propensity score matching was performed, and matched cohorts were compared using Cox proportional HRs. The primary outcome was major bleeding resulting in hospitalisation based on International Classification of Diseases (ICD)-10 codes. Secondary outcomes included intracranial bleeding, gastrointestinal bleeding and other bleeding. Exploratory outcomes included ischaemic stroke/systemic embolism and all-cause/cardiovascular (CV) mortality.Results A total of 12 103 patients met the inclusion criteria and 8686 patients were included after propensity score matching. Rates of major bleeding were similar in the apixaban (4.3/100 patient-years) and warfarin cohort (4.5/100 patient-years) (HR: 1.03; 95% CI: 0.76 to 1.39) during median follow-up of 4.4 months. Similar findings were observed for secondary outcomes including gastrointestinal bleeding and other bleeding, and exploratory outcomes including ischaemic stroke/systemic embolism and all-cause/CV mortality.Conclusions Among patients treated with amiodarone in combination with apixaban or warfarin, major bleeding and thromboembolic events were rare and with no significant difference between the treatment groups.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

atrial fibrillation
pharmacology
clinical
epidemiology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy